Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
1979 2
1980 2
1988 1
1989 1
1991 2
1992 1
1993 2
1994 4
1995 1
1996 1
1997 1
1998 2
1999 3
2000 3
2001 1
2005 1
2006 6
2007 1
2008 3
2009 3
2010 2
2011 3
2012 1
2013 2
2014 1
2015 8
2016 2
2017 5
2018 4
2019 5
2020 5
2021 7
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P, Lecomte T, Assenat E, Bauguion L, Ychou M, Bouché O, Monard L, Lambert A, Hammel P; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. Conroy T, et al. JAMA Oncol. 2022 Nov 1;8(11):1571-1578. doi: 10.1001/jamaoncol.2022.3829. JAMA Oncol. 2022. PMID: 36048453 Free PMC article. Clinical Trial.
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. Conroy T, et al. Among authors: legoux jl. N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775. N Engl J Med. 2018. PMID: 30575490 Clinical Trial.
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Bennouna J, et al. Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16. Lancet Oncol. 2013. PMID: 23168366 Clinical Trial.
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C; LAP07 Trial Group. Hammel P, et al. JAMA. 2016 May 3;315(17):1844-53. doi: 10.1001/jama.2016.4324. JAMA. 2016. PMID: 27139057 Clinical Trial.
Rectal cancer.
Legoux JL, Lehur PA, Penna C, Calais G, Roseau G, Calan LD. Legoux JL, et al. Gastroenterol Clin Biol. 2006 Sep;30 Spec No 2:2S43-2S51. Gastroenterol Clin Biol. 2006. PMID: 17151562 Free article. Review. No abstract available.
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.
Lepage C, Phelip JM, Lievre A, Le-Malicot K, Dahan L, Tougeron D, Toumpanakis C, Di-Fiore F, Lombard-Bohas C, Borbath I, Coriat R, Lecomte T, Guimbaud R, Petorin C, Legoux JL, Michel P, Scoazec JY, Smith D, Walter T. Lepage C, et al. Among authors: legoux jl. Eur J Cancer. 2022 Nov;175:31-40. doi: 10.1016/j.ejca.2022.07.033. Epub 2022 Sep 7. Eur J Cancer. 2022. PMID: 36087395 Free article. Clinical Trial.
French guidelines for digestive cancers.
Bedenne L, Dorval E, Tusseau F, Ducreux M, Legoux JL, Louvet C, Mornex F, Panis Y, Bretagne JF, Amouretti M. Bedenne L, et al. Among authors: legoux jl. Gastroenterol Clin Biol. 2006 Sep;30 Spec No 2:2S3-2S4. Gastroenterol Clin Biol. 2006. PMID: 17151557 Free article. No abstract available.
FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).
Aparicio T, Linot B, Le Malicot K, Bouché O, Boige V, François E, Ghiringhelli F, Legoux JL, Ben Abdelghani M, Phelip JM, Faroux R, Dahan L, Taieb J, Bedenne L. Aparicio T, et al. Among authors: legoux jl. Dig Liver Dis. 2015 Apr;47(4):271-2. doi: 10.1016/j.dld.2015.01.146. Epub 2015 Jan 20. Dig Liver Dis. 2015. PMID: 25677925 No abstract available.
[What can be done for digestive cancer in 1999? Recommendations of the French Foundation of Digestive Cancer (1st Part)].
Barbare JC, Bedenne L, Bouché O, Cadiot G, Calais G, de Calan L, Conroy T, Ducreux M, Etienne PL, Elias D, Faivre J, Legoux JL, Maingon P, Mornex F, Nordlinger B, Ollier JC, Peiffert D, Pelletier G, Rat P, Rougier P, Ruskone-Fourmestraux A, Seitz JF, Triboulet JP, Trinchet JC, Ychou M, et al. Barbare JC, et al. Among authors: legoux jl. Gastroenterol Clin Biol. 1999 Apr;23(4):502-12. Gastroenterol Clin Biol. 1999. PMID: 10416114 Free article. Review. French. No abstract available.
85 results